202 related articles for article (PubMed ID: 8591903)
1. Efficacy of (S)-HPMPA against thymidine kinase-deficient herpes simplex virus-keratitis.
Maudgal PC; De Clercq E; Huyghe P
Invest Ophthalmol Vis Sci; 1987 Feb; 28(2):243-8. PubMed ID: 8591903
[TBL] [Abstract][Full Text] [Related]
2. Effects of phosphonylmethoxyalkyl-purine and -pyrimidine derivatives on TK+ and TK- HSV-1 keratitis in rabbits.
Maudgal PC; De Clercq E
Antiviral Res; 1991 Jul; 16(1):93-100. PubMed ID: 1663731
[TBL] [Abstract][Full Text] [Related]
3. (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis.
Maudgal PC; De Clercq E
Invest Ophthalmol Vis Sci; 1991 May; 32(6):1816-20. PubMed ID: 1851733
[TBL] [Abstract][Full Text] [Related]
4. A novel selective broad-spectrum anti-DNA virus agent.
De Clercq E; Holý A; Rosenberg I; Sakuma T; Balzarini J; Maudgal PC
Nature; 1986 Oct 2-8; 323(6087):464-7. PubMed ID: 3762696
[TBL] [Abstract][Full Text] [Related]
5. Ocular penetration and efficacy of chloroethyldeoxyuridine against herpetic keratouveitis.
Maudgal PC; De Clercq E; Bernaerts R; Dieltiens M; Breemersch M; Van Eeckhoutte L
Invest Ophthalmol Vis Sci; 1986 Oct; 27(10):1453-8. PubMed ID: 3759363
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of 9-(2-phosphonylmethoxyethyl)adenine in the therapy of TK+ and TK- herpes simplex virus experimental keratitis.
Maudgal PC; De Clercq E
Curr Eye Res; 1991; 10 Suppl():139-42. PubMed ID: 1650660
[TBL] [Abstract][Full Text] [Related]
7. Experimental thymidine kinase-deficient HSV-1 keratitis: therapeutic attempts.
Maudgal PC; De Clercq E; Huyghe P
Curr Eye Res; 1987 Apr; 6(4):579-84. PubMed ID: 2953558
[TBL] [Abstract][Full Text] [Related]
8. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells.
Balzarini J; Bohman C; Walker RT; de Clercq E
Mol Pharmacol; 1994 Jun; 45(6):1253-8. PubMed ID: 8022417
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2'-deoxyuridine.
Wilber BA; Docherty JJ
J Gen Virol; 1994 Jul; 75 ( Pt 7)():1743-7. PubMed ID: 8021603
[TBL] [Abstract][Full Text] [Related]
10. 5-Iodo-2'-deoxy-L-uridine and (E)-5-(2-bromovinyl)-2'-deoxy-L-uridine: selective phosphorylation by herpes simplex virus type 1 thymidine kinase, antiherpetic activity, and cytotoxicity studies.
Spadari S; Ciarrocchi G; Focher F; Verri A; Maga G; Arcamone F; Iafrate E; Manzini S; Garbesi A; Tondelli L
Mol Pharmacol; 1995 Jun; 47(6):1231-8. PubMed ID: 7603465
[TBL] [Abstract][Full Text] [Related]
11. Characterization and susceptibility to antiviral agents of herpes simplex virus type 1 containing a unique thymidine kinase gene with an amber codon between the first and the second initiation codons.
Saijo M; Suzutani T; Mizuta K; Kurane I; Morikawa S
Arch Virol; 2008; 153(2):303-14. PubMed ID: 18066636
[TBL] [Abstract][Full Text] [Related]
12. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.
Balzarini J; De Clercq E; Verbruggen A; Ayusawa D; Seno T
Mol Pharmacol; 1985 Dec; 28(6):581-7. PubMed ID: 3001499
[TBL] [Abstract][Full Text] [Related]
13. Carbocyclic 5-iodo-2'-deoxyuridine (C-IDU) and carbocyclic (E)-5-(2-bromovinyl)-2'-deoxyuridine (C-BVDU) as unique examples of chiral molecules where the two enantiomeric forms are biologically active: interaction of the (+)- and (-)-enantiomers of C-IDU and C-BVDU with the thymidine kinase of herpes simplex virus type 1.
Balzarini J; De Clercq E; Baumgartner H; Bodenteich M; Griengl H
Mol Pharmacol; 1990 Mar; 37(3):395-401. PubMed ID: 2156153
[TBL] [Abstract][Full Text] [Related]
14. [Sensitivities to other antiviral drugs and thymidine kinase activity of aciclovir-resistant herpes simplex virus type 1].
Nitta K; Shiota H; Naito T; Mimura Y
Nippon Ganka Gakkai Zasshi; 1994 Jun; 98(6):513-9. PubMed ID: 8030564
[TBL] [Abstract][Full Text] [Related]
15. Increased sensitivity of thymidine kinase-deficient (TK-) tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds.
Balzarini J; De Clercq E; Verbruggen A; Crumpacker C; Ayusawa D; Seno T
Anticancer Res; 1986; 6(5):1077-84. PubMed ID: 2432829
[TBL] [Abstract][Full Text] [Related]
16. (E)-5-(2-bromovinyl)-2'-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase--expressing cells.
Hamel W; Zirkel D; Mehdorn HM; Westphal M; Israel MA
Cancer Gene Ther; 2001 May; 8(5):388-96. PubMed ID: 11477459
[TBL] [Abstract][Full Text] [Related]
17. Selection of HSV-1 TK gene-transfected murine mammary carcinoma cells resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and ganciclovir (GCV).
Degrève B; De Clercq E; Balzarini J
Gene Ther; 2000 Sep; 7(18):1543-52. PubMed ID: 11021592
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of antiviral agents in feline herpetic keratitis: results of an in vitro study.
Williams DL; Fitzmaurice T; Lay L; Forster K; Hefford J; Budge C; Blackmore K; Robinson JC; Field HF
Curr Eye Res; 2004; 29(2-3):215-8. PubMed ID: 15512970
[TBL] [Abstract][Full Text] [Related]
19. (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).
De Clercq E
Med Res Rev; 2005 Jan; 25(1):1-20. PubMed ID: 15389733
[TBL] [Abstract][Full Text] [Related]
20. A human apolipoprotein E mimetic peptide effectively inhibits HSV-1 TK-positive and TK-negative acute epithelial keratitis in rabbits.
Bhattacharjee PS; Neumann DM; Hill JM
Curr Eye Res; 2009 Feb; 34(2):99-102. PubMed ID: 19219680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
